22 completed, 2 not yet recruiting, 2 recruiting, 2 unknown. 28 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 28 | Completed 22, Not yet recruiting 2, Recruiting 2, Unknown 2 |
Follow Glabellar Lines: new trials by email Literature Review of Glabellar Lines trials Research Report on Glabellar Lines
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of DWP450 in Japanese Subjects With Glabellar Lines DWP450 20 U, 0.9% Saline Solution 0.5 mL - Glabellar Lines | Phase 3 | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 120 | 2027-01-01 | 2026-08-26 |
| To Evaluate HU-045 With Moderate to Severe Glabellar Lines HU-045, Xeomin® - Glabellar Lines | Phase 3 | Recruiting | Huons Biopharma | 390 | 2026-09-03 | 2026-10-13 |
| Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines DWP712 inj., Botox® 100 Units - Glabellar Lines | Phase 3 | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 324 | 2025-07-15 | 2025-06-10 |
| To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III) HU-045, Xeomin® - Glabellar Lines | Phase 3 | Recruiting | Huons Biopharma | 312 | 2024-06-20 | 2024-10-03 |
| A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines Abobotulinumtoxin A (Espad Pharmed Darou Co.), Abobotulinumtoxin A (Ipsen Co.) - Glabellar Lines, Glabellar Frown Lines | Phase 3 | Completed | Espad Pharmed | 146 | 2024-05-28 | 2025-05-07 |
| A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines AGN-151586, Placebo - Glabellar Lines | Phase 3 | Completed | AbbVie | 161 | 2024-03-29 | 2026-06-26 |
| Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines Botulinum Toxin Type A Injection [HG102], Botulinum Toxin Type A Injection [Botox] - Glabellar Lines | Phase 3 | Unknown | Hugel | 272 | 2024-01-04 | 2024-01-16 |
| Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial CKDB-501A, Botox® - Glabellar Lines | Phase 3 | Completed | CKD Bio Corporation | 300 | 2023-04-13 | 2023-12-12 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines Placebo, AGN-151586 - Glabellar Lines | Phase 3 | Completed | AbbVie | 638 | 2022-03-16 | 2024-05-24 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines AGN-151586, Placebo - Glabellar Lines | Phase 3 | Completed | AbbVie | 309 | 2022-03-08 | 2026-02-18 |
| A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines AGN-151586 - Glabellar Lines | Phase 3 | Completed | AbbVie | 992 | 2022-02-25 | 2026-09-25 |
| Evaluate the Efficacy and Safety of INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines. Botulinum Toxin Type A Injection [INI101], Botulinum Toxin Type A Injection [Botox] - Glabellar Lines | Phase 3 | Completed | INIBIO Co., Ltd. | 292 | 2021-05-27 | 2026-06-03 |
| Treatment of Moderate to Severe Glabellar Lines (BMI2006) BMI2006, BOTOX® - Glabellar Lines | Phase 3 | Completed | BMI Korea | 278 | 2021-02-09 | 2022-09-08 |
| Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines botulinum toxin neuromodulator - Glabellar Lines, Lateral Canthal Lines | Phase 3 | Completed | Galderma R&D | 902 | 2020-01-27 | 2023-06-18 |
| MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) MT10109L Dose 1, MT10109L Dose 2, MT10109L Dose 1 + Dose 2 - Glabellar Lines, Lateral Canthal Lines | Phase 3 | Completed | Medy-Tox | 957 | 2019-10-23 | 2024-08-09 |
| MT10109L in the Treatment of Glabellar Lines MT10109L, Placebo - Glabellar Lines | Phase 3 | Completed | Medy-Tox | 234 | 2018-12-24 | 2023-07-27 |
| MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines MT10109L, Placebo - Lateral Canthal Lines, Glabellar Lines | Phase 3 | Completed | Medy-Tox | 425 | 2018-11-05 | 2023-07-17 |
| MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL) MT10109L, Placebo - Glabellar Lines, Lateral Canthal Lines | Phase 3 | Completed | Medy-Tox | 415 | 2018-10-26 | 2023-05-25 |
| Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study) Clostridium Botulinum A Toxin - Crow's Feet Lines, Glabellar Lines | Phase 3 | Unknown | Daewoong Pharmaceutical Co. LTD. | 102 | 2017-07-01 | 2017-06-12 |
| Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines. Botulinum Toxin A type for injection (Botulax®), Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®) - Glabellar Lines | Phase 3 | Completed | Hugel | 500 | 2017-05-09 | 2022-05-24 |
Showing 20 of 28. Sign in to see all of them.
Botulinum Toxins, Type A (14) · Saline Solution (3) · incobotulinumtoxinA (3) · abobotulinumtoxinA (2) · DWP450 (1) · Injections (1) · Sodium Chloride (1)
Medy-Tox (5) · AbbVie (4) · Allergan (3) · Daewoong Pharmaceutical Co. LTD. (3) · Hugel (2) · Huons Biopharma (2) · Ipsen (2) · BMI Korea (1) · CKD Bio Corporation (1) · Espad Pharmed (1) · Galderma R&D (1) · GlaxoSmithKline (1) · INIBIO Co., Ltd. (1) · Merz Pharmaceuticals GmbH (1)
United States (11) · Canada (8) · Germany (8) · South Korea (8) · China (3) · France (3) · United Kingdom (3) · Belgium (2) · Japan (2) · Puerto Rico (2) · Russia (2) · Hungary (1) · Iran (1) · Poland (1) · Taiwan (1)
SangMi Park (4) · Alireza Firooz, Medical Doctor (1) · Beom Joon Kim, MD, Ph.D. (1) · Beomjoon Kim (1) · Berthold Rzany, Prof. Dr. med Sc.M. (1) · Timothy Corcoran Flynn, MD (1)
PMID 23190342, PMID 36206385, PMID 40586136
2014 (4), 2018 (1)